Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 2

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Down Syndrome 1

Interventions

Cyclophosphamide 30fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 18Tacrolimus 17Mycophenolic Acid 16Methotrexate 16Whole-Body Irradiation 14Etoposide 13Vincristine 12Doxorubicin 12Dexamethasone 11Busulfan 11Cytarabine 10Antilymphocyte Serum 10venetoclax 9Prednisone 9nelarabine 8Rituximab 8Filgrastim 8Cyclosporine 8Calcium Dobesilate 8merphos 7Melphalan 7Radiotherapy 6prednylidene 5deltacortene 5Methylprednisolone 5Azacitidine 5Sirolimus 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × calaspargase pegol × Clear all
NCT06390319 2026-05-01

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

St. Jude Children's Research Hospital

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

M.D. Anderson Cancer Center

Phase 2 Recruiting
22 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

National Cancer Institute (NCI)

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡